Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Blood (2025) 146 (Supplement 1): 670.

https://doi.org/10.1182/blood-2025-670

Published: 2025

Journal Articles

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

Anna Torrent, Mireia Morgades, Susana Barrera, Jordi Ribera, Eulàlia Genescà, José González-Campos, Nuria Martinez-Cibrian, Pau Montesinos, Alberto Hernández-Sánchez, Pere Barba, Edgar Zapico, Ricardo Sanchez, Marta Sitges Arriaga, Clara Maluquer Artigal, Esperanza Such, Carmen Botella, Maria Queipo De Llano, Mónica Cabrero Calvo, Ana Maria Vicent Castelló, Paula Lopez de Ugarriza, Mar Tormo, Bernardo Gonzalez Gonzalez, Irene García-Cadenas, Carlos Rodriguez Medina, Pilar Martínez-Sánchez, Arancha Bermúdez, Ignacio Gómez-Centurión, María Herrero García, Juana Ciudad, María Hermosín-Ramos, Josefina Serrano, Jose Angel Raposo Puglia, Laura Solán Blanco, Verónica Roldán Galiacho, María Almudena De Laiglesia Lorenzo, Lucía Gómez Pérez, María Solé Rodriguez, Mará Sol Casado Calderón, Laura Llorente González, Daniel Barrios Decoud, Ferran Vall-Llovera Calmet, Lorenzo Algarra, María Lourdes Amador Barciela, Raimundo Garcia, Antonia Cladera Serra, Juan Miguel Bergua Burgues, Isabel Granada, Jesus Maria Hernandez Rivas, Alberto Orfao, Josep-Maria Ribera

Blood (2025) 146 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2025-1564

Published: 2025

Journal Articles

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Blood (2025) 146 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2025-3345

Published: 2025

Journal Articles

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2025-1944

Published: 2025

Journal Articles

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

Blood (2025) 146 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2025-2369

Published: 2025

Journal Articles

ST2 as a biomarker of cytokine release syndrome following CD19-targeted chimeric antigen receptor T-cell therapy

Guillermo Orti, Cecilia Carpio, Gloria Iacoboni, Lorenzo Carita, Samantha Feijoo, Corrado Benevolo Savelli, Mario Sánchez-Salinas, Alfredo Rivas-Delgado, Víctor Navarro Garces, Sergi Cantenys-Molina, Monica Martinez, Miguel Gonzalez, Marta Crespo, Pau Abrisqueta, Francesc Bosch Albareda, Pere Barba

Blood (2025) 146 (Supplement 1): 2365.

https://doi.org/10.1182/blood-2025-2365

Published: 2025

Journal Articles

Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results

Claire Roddie, Maria Leandro, Ben Parker, Eleni Tholouli, David Jayne, Ben Uttenthal, Josefina Cortés-Hernández, Pere Barba, José Andrés Román Ivorra, Yanqing Hu, Wolfram Brugger, Silvia Basilico, Davide Germano, Ruth Pepper

Blood (2025) 146 (Supplement 1): 815.

https://doi.org/10.1182/blood-2025-815

Published: 2025

Journal Articles

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Blood (2025) 146 (Supplement 1): 811.

https://doi.org/10.1182/blood-2025-811

Published: 2025

Journal Articles

Subgroup analysis in pediatric patients from the Phase 3 study of tabelecleucel for allogeneic or solid organ transplant recipients with Epstein–Barr virus-driven post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE)

Sonali Chaudhury, Ran Reshef, Sarah Nikiforow, Diane M. George, Neena Kapoor, Michael Kent, Joerg Krueger, Theresa Cole, Pere Barba, Eduardo Olavarria, Roberta Valenti, Anke Friedetzky, Sandrine Roye, Susan Prockop

Blood (2025) 146 (Supplement 1): 5488.

https://doi.org/10.1182/blood-2025-5488

Published: 2025

Journal Articles

The cns-IPI score is predictive of severe immune effector cell-associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B-cell lymphoma

Sergi Camarillas, Samantha Feijoo, Anna Aguilera Romero, Corrado Benevolo Savelli, Víctor Navarro Garces, Andreu Vilaseca, Maria Landwehr, Helena Ariño, Marina Serra, Marc Bosch-Schips, Cristina García Herce, Cecilia Carpio, Mario Sánchez-Salinas, Alfredo Rivas-Delgado, Pau Abrisqueta, Francesc Bosch Albareda, Pere Barba, Gloria Iacoboni

Blood (2025) 146 (Supplement 1): 5498.

https://doi.org/10.1182/blood-2025-5498

Published: 2025

Journal Articles

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2025-5497

Published: 2025

Journal Articles

Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial

Blood (2025) 146 (Supplement 1): 5121.

https://doi.org/10.1182/blood-2025-5121

Published: 2025

Journal Articles

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

Claire Roddie, Jae Park, Eleni Tholouli, Karamjeet Sandhu, Paul Shaughnessy, Pere Barba, Manuel Guerreiro, Deborah Yallop, Aaron Logan, Mehrdad Abedi, Pierre Lao-Sirieix, Ping Wang, Wolfram Brugger, Bijal Shah, Anthony Hunter, Daniel Deangelo, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2025-5118

Published: 2025

Journal Articles

Impact of extranodal involvement on bispecific antibody (BsAb) outcomes in patients with large B-cell lymphoma (LBCL)

Blood (2025) 146 (Supplement 1): 1962.

https://doi.org/10.1182/blood-2025-1962

Published: 2025

Journal Articles

Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies

Blood (2025) 146 (Supplement 1): 782.

https://doi.org/10.1182/blood-2025-782

Published: 2025

Journal Articles

Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML

Marion Subklewe, Nicolas Boissel, Stephan Mielke, Pere Barba, Elisa Sala, Eric Deconinck, Olivia Fiere, Jonathan Jaeger, Chloe Vasseghi, Marina Deschamps, Christophe Ferrand, Edouard De Dreuzy, Richard Sainson, Jens Hasskarl

Blood (2024) 144 (Supplement 1): 2883.2.

https://doi.org/10.1182/blood-2024-203204

Published: 2024

Journal Articles

Consolidative Allogenic Hematopoietic Cell Transplantation Vs. Watch and Wait Strategy for B-Cell Acute Lymphoblastic Leukemia Patients with Early Loss of B-Cell Aplasia after Chimeric Antigen Receptor T-Cell Therapy

Sergi Camarillas, Anna Alonso-Saladrigues, Agueda Molinos Quintana, Víctor Navarro, Blanca Herrero-Velasco, Mario Sánchez-Salinas, Berta González-Martínez, Ana Africa Martin Lopez, Anna Torrent, Julia Marsal, Juan Luis Reguera, Gloria Iacoboni, Antonio Pérez-Martínez, Susana Rives, Pere Barba

Blood (2024) 144 (Supplement 1): 5898.

https://doi.org/10.1182/blood-2024-205932

Published: 2024

Journal Articles

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 112.

https://doi.org/10.1182/blood-2024-201946

Published: 2024

Journal Articles

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Blood (2024) 144 (Supplement 1): 67.

https://doi.org/10.1182/blood-2024-204264

Published: 2024

Journal Articles

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Jaime Roman Diaz, Saurabh Dahiya, Francesca Emily Sillito, Maeve O'Reilly, Kai Rejeski, Veit L. Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick Locke, Jay Y. Spiegel, Najla H. Al Ali, Zachary Thompson, Jongphil Kim, Rami S. Komrokji, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7239.

https://doi.org/10.1182/blood-2024-201666

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

ST2 as a biomarker of cytokine release syndrome following CD19-targeted chimeric antigen receptor T-cell therapy

Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results

Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Subgroup analysis in pediatric patients from the Phase 3 study of tabelecleucel for allogeneic or solid organ transplant recipients with Epstein–Barr virus-driven post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE)

The cns-IPI score is predictive of severe immune effector cell-associated neurotoxicity after axicabtagene ciloleucel treatment in patients with large B-cell lymphoma

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial

Chimeric antigen receptor (CAR) T-cell persistence at month 3 predicts clinical outcomes in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with obecabtagene autoleucel (obe-cel)

Impact of extranodal involvement on bispecific antibody (BsAb) outcomes in patients with large B-cell lymphoma (LBCL)

Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies

Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML

Consolidative Allogenic Hematopoietic Cell Transplantation Vs. Watch and Wait Strategy for B-Cell Acute Lymphoblastic Leukemia Patients with Early Loss of B-Cell Aplasia after Chimeric Antigen Receptor T-Cell Therapy

“Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only